CBPE triples its money with Rosemont pharma sale(2)

The UK mid-market firm has sold Rosemont Pharmaceuticals to a US trade buyer for £180m – having more than doubled EBITDA during its period of ownership.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this